Klatka Janusz, Grywalska Ewelina, Klatka Maria, Rahnama Mansur, Polak Agnieszka, Rolinski Jacek
Department of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland.
Folia Histochem Cytobiol. 2013;51(1):59-65. doi: 10.5603/FHC.2013.009.
CD200 molecule may play a role in local tumor invasion and augmenting the metastatic capacity of squamous cell carcinoma. The objective of the study was to assess by means of flow cytometry the expression of CD200 and its receptor, CD200R, on CD83+ monocyte-derived dendritic cells (Mo-DCs), pulsed or not with autologous tumor cell lysates (aTCL) in patients who suffer from laryngeal carcinoma in comparison to healthy donors. The median value of CD200 mean fluorescence intensity (MFI) on the Mo-DCs pulsed with aTCL of the patients with laryngeal cancer was 61.94 and was statistically significantly higher than on the unpulsed Mo-DCs of these patients (24.81) and healthy donors (16.63), p = 0.0034 and p = 0.0004, respectively. Median MFI score of CD200R in specimen derived from patients with laryngeal cancer was 259.31 on Mo-DCs pulsed with aTCL, while in unpulsed Mo-DCs was 86.74 (p = 0.0035) and on the Mo-DCs from control group it was 67.51 (p = 0.0004). The obtained results showed a relation between the presence of laryngeal cancer and the expression of CD200 and CD200R molecules on the CD83+ Mo-DCs pulsed with autologous cancer cell lysates. This analysis may have implications for setting new therapeutic options for cancer immunotherapy in the future.
CD200分子可能在局部肿瘤侵袭以及增强鳞状细胞癌的转移能力中发挥作用。本研究的目的是通过流式细胞术评估与健康供体相比，喉癌患者中经或未经自体肿瘤细胞裂解物（aTCL）脉冲处理的CD83⁺单核细胞衍生树突状细胞（Mo-DC）上CD200及其受体CD200R的表达。用喉癌患者的aTCL脉冲处理的Mo-DC上CD200平均荧光强度（MFI）的中位数为61.94，在统计学上显著高于这些患者未经脉冲处理的Mo-DC（24.81）和健康供体（16.63），p值分别为0.0034和0.0004。在来自喉癌患者的样本中，用aTCL脉冲处理的Mo-DC上CD200R的MFI中位数为259.31，而在未经脉冲处理的Mo-DC上为86.74（p = 0.0035），在对照组的Mo-DC上为67.51（p = 0.0004）。所得结果表明喉癌的存在与经自体癌细胞裂解物脉冲处理的CD83⁺Mo-DC上CD200和CD200R分子的表达之间存在关联。该分析可能对未来设定癌症免疫治疗的新治疗方案具有启示意义。
